

## **FORM 4**

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB Number:** 3235-0287  
**Estimated average burden**  
**hours per response:** 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *		
<u>Mikulinsky Oleg</u>		
(Last)	(First)	(Middle)
<b>700 BROOKER CREEK BLVD</b>		
<b>SUITE 1800</b>		
<hr/>		
(Street)		
OLDSMAR	FL	34677
<hr/>		
(City)	(State)	(Zip)

<p>2. Issuer Name <b>and</b> Ticker or Trading Symbol</p> <p><b><u>CRYO CELL INTERNATIONAL INC</u></b> [ <b><u>CCEL</u></b> ]</p>	<p>5. Relationship of Reporting Person(s) to Issuer (Check all applicable)</p>
<p>3. Date of Earliest Transaction (Month/Day/Year)</p> <p><b><u>01/07/2026</u></b></p>	<p><input checked="" type="checkbox"/> Director      <input type="checkbox"/> 10% Owner</p>
	<p><input checked="" type="checkbox"/> Officer (give title below)      <input type="checkbox"/> Other (specify below)</p> <p style="text-align: center;"><b>Chief Information Officer</b></p>
<p>4. If Amendment, Date of Original Filed (Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing (Check Applicable Line)</p>
	<p><input checked="" type="checkbox"/> Form filed by One Reporting Person</p>
	<p><input type="checkbox"/> Form filed by More than One Reporting Person</p>

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								104,349	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option	\$7.49								05/21/2018	05/21/2028	Common Stock	8,000		8,000 D
Stock Option	\$7.13								09/04/2019	09/04/2029	Common Stock	4,444		4,444 D
Stock Option	\$6.55								02/27/2020	02/27/2030	Common Stock	1,333		1,333 D
Stock Option	\$8								09/23/2021 <sup>(1)</sup>	09/23/2028	Common Stock	10,000		10,000 D
Stock Option	\$11.9								12/28/2021 <sup>(2)</sup>	12/28/2028	Common Stock	20,000		20,000 D
Stock Option	\$5.88								12/22/2023 <sup>(3)</sup>	12/22/2028	Common Stock	10,000		10,000 D
Stock Option	\$7.35								01/21/2025 <sup>(4)</sup>	01/21/2030	Common Stock	10,000		10,000 D
Stock Option	\$3.54	01/07/2026		A	10,000		01/07/2026 <sup>(5)</sup>		01/07/2031		Common Stock	10,000	\$3.54	10,000 D
Stock Option	\$3.54	01/07/2026		A	20,000		01/07/2026 <sup>(6)</sup>		01/07/2031		Common Stock	20,000	\$3.54	20,000 D

---

### Explanation of Responses:

1. Stock options vest 1/5 per year commencing on September 23, 2021.

2. Stock options vest immediately if the price of the Company's stock reaches \$25.00 per share during the seven year option period.
3. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
4. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
5. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

6. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least \$6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least \$8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least \$10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

/s/ Oleg Mikulinsky

\*\* Signature of Reporting Person

01/09/2026

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**